Lenacapavir will be available at low cost in 120 poor countries. But nearly all of Latin America was excluded from a deal ...
Interesting Engineering on MSN2h
From chronic to curable: Twice-yearly shot shows near-total HIV eradicationScientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
GlobalData on MSN4d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trialThe Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...
We still have 1.3 million new infections a year, the majority of which occur in marginalised and vulnerable groups. But we ...
Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to ...
Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...
How much will lenacapavir cost? Gilead charges more than €37,870 (about $40,000) per person per year for the treatment. By comparison, other prophylactic HIV medication costs an average of €50 ...
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback